Pharma BD Deal Intelligence
A $5.8B deal Abbott tried to litigate its way out of turned into its most valuable acquisition ever, as Alere's Binax rapid-testing platform became the foundation of BinaxNOW, driving roughly $8.4B in COVID-testing revenue in 2022 alone. That windfall came bundled with hundreds of millions in inherited legacy fraud settlements and a 2021 demand-forecasting misstep that saw Abbott destroy 8.6 million test cards.
A deal Abbott tried to walk away from became its single most valuable acquisition ever, thanks to the Alere/Binax rapid-testing platform's COVID-19 windfall — though it also imported hundreds of millions in legacy fraud liabilities and a bungled 2021 supply-chain reversal.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Barclays analyst Jack Meehan said remaining POC players 'carry scarcity value for strategics looking to make inroads,' and Frost & Sullivan's Divyaa…
Crain's framed deal closing as a partial win for Abbott but highlighted that Alere's sales-practice and false-claim issues would continue to drag on…
DOJ joining a 5-year-old false-claim and kickback suit against the Alere business validated Abbott's original 'substantial loss in value' complaint and…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Abbott agreed to acquire Alere for $56/share, ~$5.8B equity value, to become global leader in point-of-care diagnostics. Alere had $2.5B annual sales in infectious disease, molecular, cardiometabolic, and toxicology testing. Combined diagnostics business projected >$7B in sales. Deal later renegotiated to $51/share (~$5.3B); closed October 2017 after litigation.
A deal Abbott tried to walk away from became its single most valuable acquisition ever, thanks to the Alere/Binax rapid-testing platform's COVID-19 windfall — though it also imported hundreds of millions in legacy fraud liabilities and a bungled 2021 supply-chain reversal.
Assessment window: 5yr post-close.
$23.5B Global point-of-care diagnostics market 2016 (~$19-24B range)
Point-of-care (POC) diagnostics describes rapid, decentralized testing performed at or near the site of patient care — physician offices, ED, retail clinics, ambulances, low-resource field settings — rather than in centralized labs. Categories include infectious disease (HIV, TB, malaria, dengue, influenza, strep), cardiometabolic markers (HbA1c, BNP, troponin), and toxicology/drugs-of-abuse panels. The growth thesis at deal time was that POC platforms could compress turnaround time, improve adherence, and expand testing geography into emerging markets where central-lab infrastructure was thin.
The 2016 POC diagnostics market was estimated at roughly $19-24B globally and forecast to reach $40.5B by 2022. Pre-deal, Abbott's diagnostics franchise was anchored by core lab and the i-STAT handheld blood-gas/chemistry platform, but had thin POC infectious-disease coverage. Alere brought Determine HIV, BinaxNOW influenza/malaria, Afinion HbA1c, Triage cardiac markers, and a sizable molecular Alere q platform — alongside leadership positioning in Africa, China, and India where Frost & Sullivan flagged Alere's CD4 analyzer as the first true POC device to materially shift HIV care delivery. Direct strategic competitors at deal time included Roche Diagnostics, Danaher (post-Beckman + Cepheid 2016), Siemens Healthineers, BD, bioMérieux, and Quidel; Barclays' Jack Meehan flagged remaining standalone POC players as having 'scarcity value for strategics' looking to enter the space. The deal subsequently became contentious — Abbott alleged a 'substantial loss in value' tied to a DOJ investigation of Alere sales practices, filed suit December 2016, Alere countersued, and the parties ultimately renegotiated to $51/share (~$5.3B equity / ~$4.5B purchase price) and closed October 2017. Net: Abbott achieved POC leadership but at a discount and after roughly 18 months of friction.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Alere Inc. (this deal) | 2016 | $5.8B | 95 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
| Abbott Laboratories / Genentech, Inc. (Roche Group) | 2007 | — | 79 |
← Browse all deals · How we score deals
More: 2016 deals · Abbott Laboratories deals · Infectious Disease deals